Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 8Active not recruiting 4Terminated 2Not yet recruiting 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Head & Neck 1

Conditions

Prostatic Neoplasms 3Salivary Gland Neoplasms 1Carcinoma, Adenoid Cystic 1

Interventions

pembrolizumab 439Carboplatin 323Nivolumab 291Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 254Paclitaxel 249Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 169atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Radiosurgery 114Oxaliplatin 114Pemetrexed 113Etoposide 111Fluorouracil 110venetoclax 108fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Glutamate Carboxypeptidase II × Clear all
NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Mayo Clinic

Phase 2 Active not recruiting
45 enrolled 12 charts
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT05053152 2026-05-04

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NRG Oncology

Phase 2 Active not recruiting
194 enrolled
Genitourinary

Prostatic Neoplasms

NCT05960578 2026-04-14

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

University of Washington

Phase 2 Active not recruiting
8 enrolled
Genitourinary

Prostatic Neoplasms

NCT05924672 2026-01-14

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

University of California, San Francisco

Phase 2 Active not recruiting
2 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡